The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland

Published:2024-05-02 Issue:1 Volume:27 Page:682-696
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Mørup Michael F.¹,Taieb Vanessa²,Willems Damon³,Rose Micah⁴,Lyris Nikos⁴,Lamotte Mark⁵,Gerlier Laetitia⁶^ORCID,Thom Howard⁷⁸

Affiliation:

1. UCB Pharma, Copenhagen, Denmark

2. UCB Pharma, Colombes, France

3. UCB Pharma Brussels, Belgium

4. UCB Pharma, Slough, UK

5. Th(is)2Modeling, Asse, Belgium

6. IQVIA, Zaventem, Belgium

7. University of Bristol, Bristol, UK

8. Clifton Insight, Bristol, UK

Funder

UCB Pharma

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2342209

Reference87 articles.

1. Prevalence of axial spondylarthritis in the United States: Estimates from a cross-sectional survey

2. National Axial Spondyloarthritis Society. Axial SpA (AS) facts and figures [Internet]. 2020 [cited 2020 May 31]. Available from: https://nass.co.uk/about-as/as-facts-and-figures/

3. Is Axial Spondyloarthritis More Common Than Rheumatoid Arthritis?

4. Patient Burden of Axial Spondyloarthritis

5. Axial spondyloarthritis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP